Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Instituto de Salud Carlos III (ISCIII), C/ Monforte de Lemos 3-5, 28029, Madrid, Spain.
Departamento de Farmacología y Toxicología, Facultad de Medicina, Universidad Complutense de Madrid, Instituto Universitario de Investigación en Neuroquímica UCM, Avda. Complutense s/n, 28040, Madrid, Spain.
J Neuroinflammation. 2018 Sep 4;15(1):251. doi: 10.1186/s12974-018-1294-2.
Studies show that Toll-like receptors (TLRs), members of the innate immune system, might participate in the pathogenesis of the major depressive disorder (MDD). However, evidence of this participation in the brain of patients with MDD has been elusive.
This work explores whether the protein expression by immunodetection assays (Western blot) of elements of TLR-4 pathways controlling inflammation and the oxidative/nitrosative stress are altered in postmortem dorsolateral prefrontal cortex of subjects with MDD. The potential modulation induced by the antidepressant treatment on these parameters was also assessed. Thirty MDD subjects (15 antidepressant-free and 15 under antidepressant treatment) were matched for gender and age to 30 controls in a paired design.
No significant changes in TLR-4 expression were detected. An increased expression of the TLR-4 endogenous ligand Hsp70 (+ 33%), but not of Hsp60, and the activated forms of mitogen-activated protein kinases (MAPKs) p38 (+ 47%) and JNK (+ 56%) was observed in MDD. Concomitantly, MDD subjects present a 45% decreased expression of DUSP2 (a regulator of MAPKs) and reduced (- 21%) expression of the antioxidant nuclear factor Nrf2. Antidepressant treatment did not modify the changes detected in the group with MDD and actually increased (+ 25%) the expression of p11, a protein linked with the transport of neurotransmitters and depression.
Data indicate an altered TLR-4 immune response in the brain of subjects with MDD. Additional research focused on the mechanisms contributing to the antidepressant-induced TLR-4 pathway modulation is warranted and could help to develop new treatment strategies for MDD.
研究表明,Toll 样受体(TLR)作为先天免疫系统的成员,可能参与重度抑郁症(MDD)的发病机制。然而,MDD 患者大脑中存在这种参与的证据一直难以捉摸。
本研究旨在探讨 TLR-4 通路控制炎症和氧化/硝化应激的元素的蛋白表达是否通过免疫检测(Western blot)发生改变,这些改变是否与 MDD 患者的死后背外侧前额叶皮质有关。还评估了抗抑郁治疗对这些参数的潜在调节作用。采用配对设计,将 30 名 MDD 患者(15 名未服用抗抑郁药,15 名服用抗抑郁药)与 30 名对照相匹配,按性别和年龄进行匹配。
TLR-4 的表达没有明显变化。在 MDD 中观察到 TLR-4 内源性配体 Hsp70(增加 33%),而不是 Hsp60,以及丝裂原活化蛋白激酶(MAPKs)p38(增加 47%)和 JNK(增加 56%)的激活形式的表达增加。同时,MDD 患者的 DUSP2(MAPKs 的调节剂)表达降低了 45%,抗氧化核因子 Nrf2 的表达降低了 21%。抗抑郁治疗并没有改变 MDD 组中检测到的变化,实际上增加了 p11 的表达(一种与神经递质和抑郁有关的转运蛋白)增加了 25%。
数据表明 MDD 患者大脑中的 TLR-4 免疫反应发生改变。需要进一步研究有助于阐明抗抑郁药诱导的 TLR-4 通路调节的机制,并可能有助于开发治疗 MDD 的新策略。